Additional milestone or royalty payments received.

No definition available.

Name:	akba_AdditionalMilestoneOrRoyaltyPaymentsReceived
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaboration agreement, expiration period.

+ References

No definition available.

+ Details

Name:	akba_CollaborationAgreementExpirationPeriod
Namespace Prefix:	akba_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaboration agreement, termination, notice period.

+ References

No definition available.

+ Details

Name:	akba_CollaborationAgreementTerminationNoticePeriod
Namespace Prefix:	akba_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Cost of research services.

+ References

No definition available.

+ Details

Name:	akba_CostOfResearchServices
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Incurred clinical and commercial development cost.

+ References

No definition available.

+ Details

Name:	akba_IncurredClinicalAndCommercialDevelopmentCost
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payment received.

+ References

No definition available.

+ Details

Name:	akba_MilestonePaymentReceived
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of performance obligations.

+ References

No definition available.

+ Details

Name:	akba_NumberOfPerformanceObligations
Namespace Prefix:	akba_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of royalty payments on sales.

+ References

No definition available.

+ Details

Name:	akba_PercentageOfRoyaltyPaymentsOnSales
Namespace Prefix:	akba_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential payment for achievement of specified commercial milestones.

+ References

No definition available.

+ Details

Name:	akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Potential payment for achievement of specified milestones.

+ References

No definition available.

+ Details

Name:	akba_PotentialPaymentForAchievementOfSpecifiedMilestones
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront cash payment received.

+ References

No definition available.

+ Details

Name:	akba_UpfrontCashPaymentReceived
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3(c))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_BilledContractReceivables
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_RegulatoryMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akba_MitsubishiTanabePharmaCorporationCollaborationAgreementGlobalPhase3ProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_DevelopmentRegulatoryAndCommercialEventsMilestonesPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_DevelopmentMilestonesPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_CommercialMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_UpfrontPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=akba_ContractWithCustomerLiabilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License, Collaboration and Other Significant Agreements - Mitsubishi Tanabe Pharma Corporation Collaboration Agreement (Details)		3 Months Ended
	Dec. 11, 2015 USD ($)	Mar. 31, 2021 USD ($) performanceObligation	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Sep. 30, 2019 USD ($)	May 10, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue		$ 52,304,000			$ 88,478,000
Revenue recognized		5,382,000			10,130,000
Deferred revenue		37,552,000
Short-term deferred revenue		18,253,000						$ 15,214,000
Deferred revenue, net of current portion		19,299,000						25,345,000
Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable		3,539,000			84,566,000			$ 3,045,000	$ 15,822,000
License, collaboration and other revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue		21,896,000			59,269,000
Mitsubishi Tanabe Pharma Corporation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue		400,000
Mitsubishi Tanabe Pharma Corporation \| License, collaboration and other revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue		18,000			0
Mitsubishi Tanabe Pharma Corporation \| Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue		$ 25,000,000.0
Mitsubishi Tanabe Pharma Corporation \| Mitsubishi Tanabe Pharma Corporation Collaboration Agreement, Global Phase 3 Program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from collaborators	$ 0
Mitsubishi Tanabe Pharma Corporation \| Development and Commercialize Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue	$ 10,000,000.0
Collaboration agreement, expiration period	10 years
Collaboration agreement, notice period for termination	12 months
Upfront cash payment received	$ 20,000,000.0
Additional milestone or royalty payments received	$ 0
Number of performance obligations \| performanceObligation		2
Deferred revenue		$ 5,897,000
Short-term deferred revenue		5,897,000
Deferred revenue, net of current portion		0
Mitsubishi Tanabe Pharma Corporation \| Development and Commercialize Collaboration Agreement \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payments on sales	13.00%
Mitsubishi Tanabe Pharma Corporation \| Development and Commercialize Collaboration Agreement \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payments on sales	20.00%
Mitsubishi Tanabe Pharma Corporation \| Development and Commercialize Collaboration Agreement \| Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue	$ 25,000,000.0		$ 15,000,000.0			$ 10,000,000.0
Mitsubishi Tanabe Pharma Corporation \| Development and Commercialize Collaboration Agreement \| Regulatory Milestone Payments \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront cash payment received	40,000,000.0
Mitsubishi Tanabe Pharma Corporation \| Development and Commercialize Collaboration Agreement \| Development Regulatory And Commercial Events Milestones Payment \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone revenue	225,000,000.0
Mitsubishi Tanabe Pharma Corporation \| Development and Commercialize Collaboration Agreement \| Development Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue	10,000,000.0
Mitsubishi Tanabe Pharma Corporation \| Development and Commercialize Collaboration Agreement \| Commercial Milestone Payments \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone revenue (up to)	175,000,000.0
Mitsubishi Tanabe Pharma Corporation \| Development and Commercialize Collaboration Agreement \| Upfront Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Incurred clinical and commercial development cost	$ 20,500,000
Mitsubishi Tanabe Pharma Corporation \| Development And Commercialize Research And License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue		10,000,000.0
Upfront cash payment received		20,000,000.0
Cost of research services		20,500,000
Accounts receivable		0
Deferred revenue		0
Mitsubishi Tanabe Pharma Corporation \| Development And Commercialize Research And License Agreement \| Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue		10,000,000.0
Mitsubishi Tanabe Pharma Corporation \| Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront cash payment received				$ 10,400,000
Revenue recognized		0			$ 0
Deferred revenue, net of current portion		0
Mitsubishi Tanabe Pharma Corporation \| Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited \| Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable		0
Mitsubishi Tanabe Pharma Corporation \| Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited \| Other Current Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Short-term deferred revenue		2,200,000
Mitsubishi Tanabe Pharma Corporation \| Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited \| Other Noncurrent Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue, net of current portion		1,400,000
Mitsubishi Tanabe Pharma Corporation \| Mitsubishi Tanabe Pharma Corporation Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized		0
Up-front payments invoiced		4,400,000
Mitsubishi Tanabe Pharma Corporation \| Mitsubishi Tanabe Pharma Corporation Supply Agreement \| Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payments invoiced							$ 2,600,000
Mitsubishi Tanabe Pharma Corporation \| Mitsubishi Tanabe Pharma Corporation Supply Agreement \| Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payments invoiced		3,400,000
Mitsubishi Tanabe Pharma Corporation \| Mitsubishi Tanabe Pharma Corporation Supply Agreement \| Other Current Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payments invoiced		12,200,000
Mitsubishi Tanabe Pharma Corporation \| Mitsubishi Tanabe Pharma Corporation Supply Agreement \| Other Noncurrent Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payments invoiced		5,400,000
Mitsubishi Tanabe Pharma Corporation \| Mitsubishi Tanabe Pharma Corporation Supply Agreement \| Contract With Customer, Liability
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payments invoiced		$ 5,900,000